Abstract
The efficacy and safety of tacrolimus (FK506) ointment on atopic dermatitis (AD) was evaluated on EBM. 59 clinical studies has been so far published among 182 English and 171 Japanese papers selected by the keywords, tacrolimus and AD. Several randomized, double-blind, multicenter studies successfully showed the effectiveness of tacrolimus ointment on AD and the consecutive studies also claimed no severe side effects except some adverse events such as transient irritation at the site of application. The similar effectiveness of tacrolimus ointment compared to very strong class topical corticosteroid was further confirmed in randomized, double-blind, multicenter study. In conclusion, the clinical efficacy and safety of tacrolimus ointment on AD has been established on EBM.
